Recent progress in direct-acting antiviral agents for chronic hepatitis C / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 493-495, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-498959
ABSTRACT
The current standard treatment for hepatitis C virus (HCV)infection is a combination of pegylated interferon (PEG-IFN)and ribavirin.However,it remains incurable in some patients.In recent years,direct acting antiviral agents (DAAs)that target specific HCV enzymes in HCV life cycle have been developed rapidly.A combination of PEG-IFN,ribavirin,and DAAs can increase the sustained viro-logical response rate in patients with chronic hepatitis C (CHC).For patients who cannot use or tolerate interferon therapy,a combination of various DAAs has good efficacy.Therefore,DAAs bring new hope for the treatment of CHC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Clinical Hepatology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS